Advertisement

Archives of oto-rhino-laryngology

, Volume 221, Issue 3, pp 221–225 | Cite as

First clinical experiences with hormone-therapy of pachydermia laryngis

  • B. Hussl
  • K. Loewit
  • E. Richter
  • S. Schwarz
Short Communications

Summary

First clinical experiences with the anti-androgenic drug cyproteroneacetate in treatment of pachydermia laryngis are reported in eleven male and female patients. This endocrine therapy led to complete healing in four and to marked improvement in six patients. One did not respond. Evaluation of the endocrine state of these patients showed imbalance in the androgen/estrogen equilibrium. As the larynx constitutes a secondary sex characteristic and an endocrine target organ, the significance of endocrine factors for pathogenesis and therapy of epithelial changes on the vocal cords is discussed.

Key words

Larynx Pachydermia laryngis Hormonetherapy Antiandrogens Cyproterone-acetate 

Zusammenfassung

Es wird über erste klinische Erfahrungen in der Behandlung der Pachydermia laryngis mit dem Testosteronantagonisten Cyproteronazetat an elf Patienten beiderlei Geschlechts berichtet. Diese neuartige Therapie führte in vier Fällen zu vollständiger Heilung, bei sechs Patienten zu wesentlicher Besserung und blieb in einem Fall erfolglos! Hormonbestimmungen deckten Störungen im Androgen/Östrogen-Gleichgewicht auf. Die Bedeutung endokriner Faktoren für die Pathogenese und die Therapie von Epithelveränderungen im Larynx als einem sekundären Geschlechtsmerkmal wird diskutiert.

Schlüsselwörter

Larynx Pachydermie Hormonbehandlung Antiandrogene Cyproteronazetat 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Duchon, J., Czigner, J., Pupp, L.: Stimmbandpachydermie und das Rauchen. Z. Laryng. Rhinol.51, 253–257 (1972)Google Scholar
  2. Girard, J., Baumann, J. B.: Secondary adrenal insufficiency due to cyproterone-acetate. J. Endocrinol.69, 13 (1976)Google Scholar
  3. Habib, F. K., Lee, J. R., Stitch, S. R., Smith, P. H.: Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate. J. Endocrinol.71, 99–107 (1976)PubMedGoogle Scholar
  4. Hervy, T., Jordan, J., Lorkiewicz, H.: Preliminary evaluation of progression of disease and results of treatment in patients with laryngeal carcinoma in the material of the Medical Academy in Gdansk. Otolaryngol. Pol.27, 437–440 (1973)PubMedGoogle Scholar
  5. Loewit, K.: Zum Problem Larynxkarzinom und Sexualhormone. Mschr. Ohrenheilk.97, 436–439 (1963)PubMedGoogle Scholar
  6. Loewit, K., Hussl, B., Richter, E., Schwarz, S.: Antiandrogen therapy in pachydermia of the female larynx — a new therapeutic possibility. Arch. Otorhinolaryngol. (N.Y.)215, 75–79 (1977)Google Scholar
  7. Loewit, K., Schwarz, S., Hussl, B., Richter, E.: Urinary androgen and estrogen excretion in men with pachydermia laryngis and cancer of the larynx. (submitted Endokrinologie 1978)Google Scholar
  8. Neumann, F.: Use of cyproterone-acetate in animal and clinical trials. Gynecol. Invest.2, 150 (1971)PubMedGoogle Scholar
  9. Ruppmann, E.: Beziehungen zwischen Larynxcarcinom und exogenen Faktoren. HNO8, 246–248 (1960)PubMedGoogle Scholar
  10. Saez, S., Sakai, F.: Récepteurs d'androgénes: mise en évidence dans la fraction cytosolique de muqueuse normale et d'épithéliomas pharyngolaryngés humains. C.R. Acad. Sci. (Paris)280, 935–938 (1975)Google Scholar
  11. Saez, S., Sakai, F.: Androgen receptors in human pharyngolaryngeal mucosa and pharyngo-laryngeal epithelioma. J. Steroid Biochem.7, 919–921 (1976)PubMedGoogle Scholar
  12. Stell, P. M.: Smoking and laryngeal cancer. Lancet1972 I, 617–619Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • B. Hussl
    • 1
  • K. Loewit
    • 1
  • E. Richter
    • 1
  • S. Schwarz
    • 1
  1. 1.Department of Otolaryngology, Institute of Experimental PathologyUniversity of InnsbruckInnsbruckAustria

Personalised recommendations